CD ComputaBio has in-depth communication with clients in the development of preclinical integrated study protocols for ADCs. The scientific backbone combines the characteristics of each case with years of practical experience and technical accumulation, and carefully submits quality experimental protocols and results to clients. With our expertise in computational biology and medicinal chemistry, we offer customized solutions for the design and optimization of antibody drug conjugates (ADCs) targeting specific cancer cells.
The three major components of ADC drugs are: 1) specific targeting antibodies, 2) toxins, and 3) cleavable/non-cleavable linkers. The development of ADC drugs has a high technical barrier, which requires a combination of factors such as the rational selection of targets, the rational combination of antibodies, linkers, small molecule drugs and the rational combination between them, the antibody coupling technology and the drug resistance of ADC drugs. Among them, target selection, linker selection, coupling technology and preclinical efficacy evaluation are the focus of attention in the ADC development process.
CD ComputaBio can provide services such as:
At CD ComputaBio, with our expertise in computational biology and medicinal chemistry, we offer customized solutions for designing and optimizing ADCs that target specific cancer cells while minimizing toxicity to healthy tissue. Our ADC drug design services are supported by advanced computational methods, state-of-the-art modeling tools, and a team of experienced scientists who are dedicated to ensuring the success of your project.